BRM421
Phase 2Small molecule
BRM421 is one of 62 small molecule programs targeting Eye Disease. It is currently in Phase 2.
2
Indications
5
Total Trials
1
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
200 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Neoral
NovartisPhase 3
Alphagan
AbbViePhase 3
Chantix
PfizerPhase 3
Bayer Aspirin
BayerPhase 3
Zovirax
BBp Consulting, Inc
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Carboxymethylcellulose
AbbViePhase 3
Csa
ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
Diquafosol Tetrasodium
Merck & Co.Phase 3
ABBV-444
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Dry Eye Syndrome2 trials
Safety and Efficacy1 trial
Eye Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BRM421. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBRIM Biotechnology Inc.